Study Published in The Lancet Reports Positive Phase 2b Results for Atopic Dermatitis Treatment

Nektar Therapeutics announced that peer-reviewed data from the 16-week induction period of its Phase 2b REZOLVE-AD study for rezpegaldesleukin in moderate-to-severe atopic dermatitis was published in The Lancet. The trial demonstrated statistically significant and clinically meaningful improvements across various disease measures. These positive findings support the continued advancement of rezpegaldesleukin into ongoing Phase 3 clinical programs, offering potential new treatment options for patients.